Related Experiment Video
Updated: Feb 19, 2026
09:04
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
10.2K
PROPHYLACTIC USE OF 15(S)15 METHYL PGF2α FOR CONTROL OF POSTPARTUM BLEEDING
Acta Obstetricia Et Gynecologica Scandinavica
|November 10, 2017
Summary
15(S)15 methyl prostaglandin F2α (Prostin 15M) effectively controlled postpartum hemorrhage by reducing bleeding and the third stage of labor duration. This oxytocic agent significantly lowered blood loss in women delivered at term.
Area of Science:
- Obstetrics and Gynecology
- Reproductive Medicine
- Pharmacology
Background:
- Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality worldwide.
- Effective management of the third stage of labor is crucial for preventing excessive blood loss.
- Oxytocic agents are commonly used to manage PPH, but their efficacy and side effect profiles vary.
Purpose of the Study:
- To evaluate the efficacy of 15(S)15 methyl prostaglandin F2α (Prostin 15M) in controlling bleeding during the third stage of labor.
- To assess the impact of Prostin 15M on the duration of the third stage of labor and overall blood loss.
- To compare the outcomes in women receiving Prostin 15M versus those receiving no oxytocic treatment.
Main Methods:
- A clinical study involving women delivered at term.
- Administration of 125 µg of Prostin 15M via intramuscular route upon delivery of the anterior shoulder.
- Measurement of blood loss and duration of the third stage of labor.
Main Results:
- Prostin 15M significantly reduced the duration of the third stage of labor.
- Blood loss was reduced to approximately one-third in the Prostin 15M group compared to controls.
- Marked reduction in blood loss was observed during the two hours following delivery with Prostin 15M treatment.
Conclusions:
- 15(S)15 methyl prostaglandin F2α is an effective agent for controlling postpartum bleeding.
- Prostin 15M offers a significant benefit in reducing both the duration of the third stage of labor and blood loss.
- This oxytocic agent represents a valuable option for PPH prevention and management.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.3K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
529
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
01:29Venous Thrombosis III: Interprofessional Care
388
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
388